/
/
/

Medicamen Biotech Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019
₹48 Cr₹61 Cr₹47 Cr₹47 Cr₹43 Cr₹30 Cr₹45 Cr₹45 Cr₹43 Cr₹47 Cr₹47 Cr₹44 Cr₹42 Cr₹39 Cr₹36 Cr₹34 Cr₹33 Cr₹23 Cr₹33 Cr₹33 Cr₹28 Cr₹21 Cr₹33 Cr₹31 Cr₹28 Cr₹24 Cr₹35 Cr₹36 Cr₹31 Cr₹24 Cr
₹86 L₹2 Cr₹54 L₹37 L₹47 L₹5 Cr₹14 L₹29 L₹59 L₹57 L₹83 L₹55 L₹38 L₹35 L₹63 L₹53 L₹96 L₹34 L₹83 L₹48 L₹8 L₹54 L₹10,000₹13 L₹8 L₹1 Cr₹45 L₹35 L₹4 L₹7 L
₹49 Cr₹62 Cr₹47 Cr₹48 Cr₹44 Cr₹35 Cr₹45 Cr₹45 Cr₹44 Cr₹48 Cr₹47 Cr₹44 Cr₹42 Cr₹39 Cr₹36 Cr₹34 Cr₹34 Cr₹23 Cr₹33 Cr₹33 Cr₹28 Cr₹22 Cr₹33 Cr₹31 Cr₹28 Cr₹25 Cr₹36 Cr₹36 Cr₹31 Cr₹24 Cr
₹45 Cr₹57 Cr₹44 Cr₹44 Cr₹40 Cr₹32 Cr₹41 Cr₹42 Cr₹41 Cr₹43 Cr₹43 Cr₹41 Cr₹37 Cr₹34 Cr₹31 Cr₹29 Cr₹29 Cr₹19 Cr₹28 Cr₹28 Cr₹23 Cr₹17 Cr₹28 Cr₹26 Cr₹24 Cr₹21 Cr₹31 Cr₹30 Cr₹27 Cr₹20 Cr
₹5 Cr₹7 Cr₹5 Cr₹6 Cr₹5 Cr₹4 Cr₹7 Cr₹6 Cr₹4 Cr₹6 Cr₹6 Cr₹5 Cr₹7 Cr₹7 Cr₹7 Cr₹6 Cr₹7 Cr₹5 Cr₹7 Cr₹7 Cr₹6 Cr₹5 Cr₹5 Cr₹6 Cr₹4 Cr₹4 Cr₹6 Cr₹6 Cr₹5 Cr₹4 Cr
₹83 L₹38 L₹97 L₹99 L₹1 Cr₹65 L₹76 L₹1 Cr₹71 L₹2 Cr₹65 L₹91 L₹96 L₹86 L₹68 L₹62 L₹77 L₹56 L₹49 L₹30 L₹4 L₹36 L₹9 L₹38 L₹24 L₹0₹19 L₹21 L₹16 L₹20 L
₹3 Cr₹5 Cr₹2 Cr₹3 Cr₹2 Cr₹2 Cr₹4 Cr₹2 Cr₹2 Cr₹3 Cr₹3 Cr₹2 Cr₹5 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹3 Cr₹5 Cr₹5 Cr₹5 Cr₹4 Cr₹4 Cr₹5 Cr₹3 Cr₹3 Cr₹5 Cr₹5 Cr₹4 Cr₹4 Cr
₹2 Cr₹4 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr₹91 L₹80 L₹2 Cr₹2 Cr₹1 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹3 Cr₹4 Cr₹4 Cr₹4 Cr₹4 Cr₹3 Cr₹3 Cr₹2 Cr₹2 Cr₹4 Cr₹4 Cr₹3 Cr₹2 Cr

Share Price Live Stats

Open (₹)301.00
Volume (₹)1.92 L
High (₹)330.00
Upper Circuit369.00
Low (₹)289.45
Lower Circuit246.00
Prev Close307.50
52W High (₹)447.65
Price323.05
52W Low (₹)212.40

Share Market Cap & Key Ratios Overview

M.Cap (₹)416.38 Cr
Div. Yield (%)0.33
PE Ratio38.45
Debt to Equity0.16
Price to Book2.97
Book Value162.23
EPS (TTM)7.98
Face Value10.00
ROE (%)3.23

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
AUROPHARMANSE
DRREDDYNSE
LUPINNSE
MANKINDNSE
MEDICAMEQNSE
LTP
1W Low
1W High
Market cap (₹)
1840-55 (-2.90%)
1834
1907.80
4,47,236Cr
9322+7 (0.08%)
9119.50
9615
2,49,673Cr
4965.5+51.5 (1.05%)
4823
5000
1,87,460Cr
1119.1-37.8 (-3.27%)
1104.60
1167.70
1,11,521Cr
1366-29 (-2.08%)
1347.70
1398.40
1,11,484Cr
1969+92.3 (4.92%)
1832.70
1981.80
1,04,604Cr
1679.8+19.8 (1.19%)
1646
1704
96,031Cr
1165.5+21.3 (1.86%)
1130
1182
95,220Cr
2095-10 (-0.48%)
2058
2135.50
94,883Cr
2280-38 (-1.64%)
2222
2331.60
92,770Cr
323.05+43.8 (15.68%)
267
330
416Cr

Key Highlights of Medicamen Biotech Ltd’s P&L

In 2025-03-31, Medicamen Biotech Ltd reported total revenue of ₹168.8Cr, compared with ₹181.63Cr in 2024-03-31, reflecting Medicamen Biotech Ltd turnover.

Depreciation was ₹7.07Cr and finance costs were ₹3.72Cr in 2025-03-31

Profit Before Tax (PBT) has been ₹9.88Cr in 2025-03-31 as compared to ₹13.08Cr in 2024-03-31.

Net Profit (PAT) was ₹6.56Cr in 2025-03-31 compared with ₹9.49Cr in 2024-03-31.

Earnings per share (EPS) were ₹5.16 in 2025-03-31, compared with ₹7.47 in 2024-03-31.